Clinical trials
CLL/SLL clinical trials
Below are recruiting cll/sll clinical trials, each written for real people, not researchers. We’re tracking 37 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06967610RecruitingPhase 2
Pirtobrutinib, venetoclax, and obinutuzumab for recurrent CLL/SLL
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
Houston, TexasAges 18 years+ - NCT06849713RecruitingPhase 2
New combination treatments for CLL or SLL
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06767891Enrolling by invitation
Acalabrutinib for mantle cell lymphoma or chronic lymphocytic leukemia
This study is looking at how well acalabrutinib works in real-world patients who have mantle cell lymphoma (MCL) or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). If you have one of these types of blood cancer and have not had certain other treatments, you may be able to join.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06539182RecruitingPhase 2
DZD8586 for relapsed or refractory CLL/SLL
This trial tests a new oral drug called DZD8586 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to previous treatment. The goal is to see if it can help control the disease.
Hefei, AnhuiAges 18 years+ - NCT05963217RecruitingPhase 1
Study of a patient’s own CAR T cells for CD19 cancers
This Phase 1 study tests a personalized form of CAR T cell treatment made from your own immune cells to fight certain CD19-positive blood cancers that have returned or not responded to prior treatment. It mainly looks at safety and how well the treatment can work.
Toronto, OntarioAges 18 years+ - NCT05791409RecruitingPhase 1/Phase 2
Venetoclax plus epcoritamab for relapsed or refractory CLL
This early-phase study tests whether combining venetoclax (a tablet) with epcoritamab (a targeted antibody) can control CLL/SLL that has come back or did not respond. It may help by boosting the immune system’s ability to attack the cancer while keeping the treatment schedule in cycles.
MelbourneAges 18 years+ - NCT05702853RecruitingPhase 1/Phase 2
CAR T-cell therapy after CD34 selection for CD19 lymphoma or CLL
This Phase 1/2 study tests a customized type of immune cell treatment (CD19 CAR T-cells) for people with certain relapsed or hard-to-treat lymphomas or CLL/SLL. It aims to improve control of disease by targeting the CD19 marker on cancer cells.
Charleston, South CarolinaAges 18 years+ - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Orange, CaliforniaAges 18 years+ - NCT05147467RecruitingPhase 2
Trial of APG-2575 for returning or resistant CLL/SLL
This trial studies APG-2575 in people with CLL/SLL that has come back or is not responding to prior treatments. It may help shrink disease and improve control when standard options have stopped working.
Guangzhou, GuangdongAges 18 years+ - NCT04775745RecruitingPhase 1
Oral drug test for relapsed or refractory B-cell blood cancers
This Phase 1 trial studies LP-168 taken by mouth in people whose B-cell cancers have come back or did not respond to treatment. The study aims to find how the drug works, the right dose, and what side effects to expect.
Durham, North CarolinaAges 18 years+ - NCT04523428RecruitingPhase 2
Second round of targeted pills after short venetoclax benefit
This trial studies whether repeating two targeted medicines—venetoclax plus acalabrutinib—for a limited time can control CLL or SLL after you had a partial response to earlier venetoclax-based treatment. It may help people who need retreatment but want another approach beyond the first limited course.
BrusselsAges 18 years+ - NCT04269902RecruitingPhase 3
Early treatment check for high-risk CLL/SLL
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
Birmingham, AlabamaAges 18 years+ - NCT00923507Recruiting
Study of blood cancers’ natural course and next treatment needs
This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.
Bethesda, MarylandAges 18–110
Hear when a new CLL/SLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cll/sll?
- Yes. Clin2 currently lists 37 recruiting cll/sll studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cll/sll trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cll/sll trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.